Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

Company Overview - Halozyme Therapeutics (HALO) shares have decreased by approximately 23.2% over the past month, underperforming the S&P 500 [1] - The company has a Zacks Rank of 2 (Buy), indicating expectations for above-average returns in the coming months [4] Earnings Estimates - Fresh estimates for Halozyme Therapeutics have shown an upward trend over the past two months [2] VGM Scores - Halozyme Therapeutics has a strong Growth Score of A, a Momentum Score of B, and a Value Score of A, resulting in an aggregate VGM Score of A [3] Industry Comparison - Halozyme operates within the Zacks Medical - Biomedical and Genetics industry, where competitor Incyte (INCY) has seen a 13.2% increase in share price over the past month [5] - Incyte reported revenues of $1.05 billion for the last quarter, reflecting a year-over-year growth of 19.5% [5] - Incyte's expected earnings for the current quarter are $1.38 per share, representing a year-over-year increase of 175.8% [6]